Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Cancer Research Technology licenses therapeutic antibodies to Peptech

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.

2 May 2007

PDL BioPharma's European patent claims upheld

PDL BioPharma has announced that the Opposition Division of the European Patent Office decided at an oral proceeding to uphold claims in the company's European Patent No. 0 451 216 ('216 patent) that are virtually identical to the claims remitted to the Opposition Division by the Board of Appeal.

25 Apr 2007

New research may help identify patients most likely to benefit from cisplatin treatment

Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors.

20 Apr 2007

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.

19 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Scientists identify protein key to breast cancer spread

(PHILADELPHIA) Researchers at the Kimmel Cancer Center at Jefferson have identified a protein that they say is key to helping a quarter of all breast cancers spread.

10 Apr 2007

ESMO explores collaboration to fight cancer on all fronts

Leading figures in the global fight against lung cancer are meeting in the city of Geneva, Switzerland this week to discuss the latest tools for preventing and treating chest malignancies, which kill more than 1.3 million people each year.

2 Apr 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007

Two novel therapies for multiple myeloma

Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

14 Mar 2007

Archemix granted two European patents

Archemix has announced today the issuance of two key, broad patents by the European Patent Office ("EPO"). The patents, EP 0 786 469 and EP 0 668 931, broadly cover methods for the identification and use of aptamers for therapeutic applications.

8 Mar 2007

New Crohn's disease treatment Humira promises to reduce symptoms

The Food and Drug Administration (FDA) in the United States has given it's approval for the use of the drug Humira (adalimumab) to treat adults suffering from Crohn's disease.

28 Feb 2007

FDA approves Humira (adalimumab) for Crohn's disease

The U.S. Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.

27 Feb 2007

Quantum rods and dots image cancer cells

Brightly fluorescent quantum dots and quantum rods are quickly becoming important tools for identifying specific molecules and cells in living systems. Two new reports demonstrate some of the ways in which cancer researchers are using these nanoscale imaging agents.

26 Feb 2007

Scientists discover master switches for adult blood stem cells

Johns Hopkins Kimmel Cancer Center scientists have found a set of "master switches" that keep adult blood-forming stem cells in their primitive state.

8 Feb 2007

Bright quantum dots help basic cancer biology studies

Though there is little doubt that nanoscale devices are going to play a critical role in improving cancer detection and treatment over the next five to ten years, nanoparticles are already having a major impact on the way that cancer biologists study the processes that go awry within malignant and metastatic cells.

5 Feb 2007

Cruelty-free ELISA for human insulin

In the January issue of Clinical Biochemistry, scientists and physicians with the Physicians Committee for Responsible Medicine (PCRM) outline the method used to develop a cruelty-free ELISA for human insulin that uses monoclonal antibodies produced by cells cultured in an animal-serum-free medium.

30 Jan 2007

Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients

The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.

18 Jan 2007

Cancer Research Technology to present discovery updates at BioEurope 2006

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that Phil L'Huillier, the Director of Business Management, will present at the BioEurope 2006 Annual International Partnering Conference.

6 Nov 2006